Oxford Science Enterprises Taps Harry Clifford for Health Tech Growth Role
Investor - People | Apr 15, 2025 | oxford sciences innovation
Oxford Science Enterprises (OSE) has appointed Harry Clifford as Entrepreneur-in-Residence (EIR) in their Health Tech team. Clifford brings extensive experience from biotechnology, AI, venture-building, and academic research. Previously part of NVIDIA's healthcare team, Clifford co-founded Cambridge Cancer Genomics and has been involved in high-profile ventures recognized internationally. His role at OSE will involve leveraging his background to accelerate Health Tech company growth, especially in AI and digital biology. Senior Partner Heather Roxborough expressed excitement about Clifford's expertise, describing it as invaluable for transforming Oxford's scientific research into startups. Clifford will work on translating groundbreaking Oxford research into impactful healthcare innovations. OSE's approach to integrating seasoned entrepreneurs has already resulted in successful spinouts within the Oxford ecosystem.
Sectors
- Biotechnology
- Artificial Intelligence
- Venture Capital
Geography
- United Kingdom – Oxford Science Enterprises is based in the UK, and the focus is on turning Oxford University's research into commercial ventures, which is central to the article.
- United States – Clifford's former company, Cambridge Cancer Genomics, was backed by Y-Combinator, a US-based accelerator, highlighting cross-border entrepreneurship activity.
Industry
- Biotechnology – The article discusses Harry Clifford's experience and future role in biotechnology, particularly in digital biology and AI-driven healthcare innovations.
- Artificial Intelligence – Clifford's prior work, particularly in AI frameworks for drug discovery, is central to his new role with OSE, which aims to leverage AI innovations in healthcare.
- Venture Capital – Oxford Science Enterprises acts as a venture-building entity, turning scientific research into viable business ventures, indicating a strong alignment with venture capital activities.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Oxford Science Enterprises | Private Equity Firm | Company | A private equity firm focused on leveraging Oxford University research to create successful commercial ventures. |
| Harry Clifford | Entrepreneur-in-Residence, Health Tech | Person | Appointed at OSE to help accelerate the growth of health tech startups using his expertise in AI and digital biology. |
| NVIDIA | Former Employer | Company | Harry Clifford's former employer, where he was involved in developing digital biology frameworks and AI-driven health tech. |
| Cambridge Cancer Genomics (CCG.ai) | Former Company | Company | A startup co-founded by Clifford that uses deep learning for cancer treatment, acquired by Dante Labs. |
| Heather Roxborough | Senior Partner, Health Tech | Person | Senior partner at OSE, who welcomed Clifford to the team emphasizing his role in future health tech ventures. |